INTRON INDUCTION THERAPY PLUS RIBAVIRIN FOR HCV (R97 024)

$3,864M01FY2000RRNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 39362046 Paper 39080017 Paper 39037383 Paper 38161124 Paper 37014543 Paper 35589527 Paper 34861039 Paper 34782257 Paper 34600842 Paper 34474518 Paper 33627633 Paper 33270130 Paper 32918404 Paper 32475754 Paper 32174061 Paper 31984660 Paper 31960977 Paper 31794512 Paper 31378475 Paper 31331758 Paper 30950861 Paper 30820886 Paper 30785625 Paper 30421853 Paper 30358155 Paper 30326125 Paper 30302964 Paper 30302961 Paper 30236542 Paper 30139560 Paper 29892045 Paper 29777230 Paper 29700388 Paper 29428999 Paper 29335242 Paper 29256014 Paper 29214306 Paper 29032053 Paper 29029184 Paper 29016506 Paper 28857792 Paper 28783531 Paper 28579202 Paper 28554178 Paper 28528115 Paper 27766453 Paper 27755626 Paper 27289123 Paper 27178608 Paper 27169694 Paper 27096225 Paper 27085231 Paper 27046364 Paper 26925541 Paper 26865065 Paper 26747209 Paper 26724517 Paper 26636177 Paper 26384391 Paper 26098620 Paper 26063668 Paper 26010326 Paper 25920773 Paper 25862182 Paper 25824474 Paper 25757445 Paper 25720600 Paper 25665815 Paper 25648736 Paper 25145603 Paper 25117987 Paper 25099744 Paper 24815959 Paper 24782263 Paper 24719222 Paper 24704178 Paper 24685959 Paper 24634371 Paper 24627273 Paper 24613131 Paper 24582483 Paper 24582008 Paper 24531558 Paper 24380645 Paper 24358296 Paper 24315560 Paper 24249816 Paper 24248833 Paper 24189773 Paper 24189698 Paper 24144652 Paper 24126768 Paper 24083102 Paper 24065153 Paper 24041677 Paper 24026554 Paper 23909945 Paper 23891147 Paper 23846811 Paper 23835882

Abstract

This is a pilot study designed to carefully examine the efficacy of different doses of interferon during the first six weeks of therapy in a selected group of patients with genotype 1 chronic hepatitis C virus (HCV) infections with varying levels of circulating virus. Patients will randomly assigned to receive 1 million units (MU), 3MU, 5MU, ot 10MU interferon alpha-2b daily for 6 weeks followed by 12 months of maintenance therapy with 3MU interferon three times a weekly plus oral ribavirin (1000-1200 mg/day). Both interferon and viral kinetics will be examined during the first weeks of treatment. In addition, viral sequences will be determined before and after the first six weeks of therapy to determine the rate at which viral resistance to interferon develops.

View original record on NIH RePORTER →